Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3608623rdf:typepubmed:Citationlld:pubmed
pubmed-article:3608623lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:3608623lifeskim:mentionsumls-concept:C1514521lld:lifeskim
pubmed-article:3608623lifeskim:mentionsumls-concept:C0001563lld:lifeskim
pubmed-article:3608623lifeskim:mentionsumls-concept:C0028365lld:lifeskim
pubmed-article:3608623lifeskim:mentionsumls-concept:C0205321lld:lifeskim
pubmed-article:3608623pubmed:issue4lld:pubmed
pubmed-article:3608623pubmed:dateCreated1987-9-23lld:pubmed
pubmed-article:3608623pubmed:abstractTextConcomitant concentrations of norfloxacin in serum, urine and prostatic tissue were determined in 12 patients following a single oral dose of 400 mg. Tissue levels ranged from 0.3 to 1.73 mg/kg, and therapeutic concentrations were demonstrable for as long as 8 h following dosage. The mean ratio of tissue to serum concentration was 1.01 +/- (SE) 0.13.lld:pubmed
pubmed-article:3608623pubmed:languageenglld:pubmed
pubmed-article:3608623pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3608623pubmed:citationSubsetIMlld:pubmed
pubmed-article:3608623pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3608623pubmed:statusMEDLINElld:pubmed
pubmed-article:3608623pubmed:issn0009-3157lld:pubmed
pubmed-article:3608623pubmed:authorpubmed-author:BergerS ASAlld:pubmed
pubmed-article:3608623pubmed:authorpubmed-author:DasJJlld:pubmed
pubmed-article:3608623pubmed:authorpubmed-author:GolombJJlld:pubmed
pubmed-article:3608623pubmed:authorpubmed-author:LindnerAAlld:pubmed
pubmed-article:3608623pubmed:authorpubmed-author:GorerPPlld:pubmed
pubmed-article:3608623pubmed:issnTypePrintlld:pubmed
pubmed-article:3608623pubmed:volume33lld:pubmed
pubmed-article:3608623pubmed:ownerNLMlld:pubmed
pubmed-article:3608623pubmed:authorsCompleteYlld:pubmed
pubmed-article:3608623pubmed:pagination240-2lld:pubmed
pubmed-article:3608623pubmed:dateRevised2009-11-11lld:pubmed
pubmed-article:3608623pubmed:meshHeadingpubmed-meshheading:3608623-...lld:pubmed
pubmed-article:3608623pubmed:meshHeadingpubmed-meshheading:3608623-...lld:pubmed
pubmed-article:3608623pubmed:meshHeadingpubmed-meshheading:3608623-...lld:pubmed
pubmed-article:3608623pubmed:meshHeadingpubmed-meshheading:3608623-...lld:pubmed
pubmed-article:3608623pubmed:meshHeadingpubmed-meshheading:3608623-...lld:pubmed
pubmed-article:3608623pubmed:meshHeadingpubmed-meshheading:3608623-...lld:pubmed
pubmed-article:3608623pubmed:meshHeadingpubmed-meshheading:3608623-...lld:pubmed
pubmed-article:3608623pubmed:meshHeadingpubmed-meshheading:3608623-...lld:pubmed
pubmed-article:3608623pubmed:year1987lld:pubmed
pubmed-article:3608623pubmed:articleTitlePenetration of norfloxacin into human prostatic tissue following single-dose oral administration.lld:pubmed
pubmed-article:3608623pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3608623pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3608623lld:pubmed